Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of all breast cancers and characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (1). This evidence concerns the gene ERBB2 and breast carcinoma.